REGENERON PHARMACEUTICALS, INC. (REGN) FY2025 Q1 P&L / Income Statement

REGENERON PHARMACEUTICALS, INC. (REGN) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

3,028,700,000 US dollars

Cost of revenue (calculated)

464,300,000 US dollars

Gross profit (calculated)

2,564,400,000 US dollars

Operating expenses (calculated)

1,972,700,000 US dollars

Income from operations

591,700,000 US dollars

Total other income (expense)

313,300,000 US dollars

Income before income taxes

905,000,000 US dollars

Income tax expense (benefit)

96,300,000 US dollars

Net income

808,700,000 US dollars

ELYEA HD And EYLEA - UNITED STATES

1,042,800,000 US dollars

ELYEA HD - UNITED STATES

306,800,000 US dollars

Evkeeza - UNITED STATES

30,900,000 US dollars

EYLEA Net Product Sales - UNITED STATES

736,000,000 US dollars

Inmazeb - Rest Of World

0 US dollars

Libtayo - UNITED STATES

192,500,000 US dollars

Libtayo - Rest Of World

92,600,000 US dollars

Praluent - UNITED STATES

56,800,000 US dollars

Undisclosed (calculated)

570,300,000 US dollars

Cost of goods sold, collaboration and contract manufacturing

464,300,000 US dollars

Other operating expense (income), net

0 US dollars

Research and development

1,327,400,000 US dollars

Acquired in-process research and development

12,300,000 US dollars

Selling, general, and administrative

633,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.